The Form Bio team, from L-R: co-CEO Andrew Busey; director of bioinformatics Brandi Cantarel; co-CEO Kent Wakeford; chief strategy officer Claire Aldridge; plus Colossal CEO Ben Lamm (Business Wire)
September 27, 2022 11:05 AM EDTUpdated 12:21 PM
Financing
Startups

George Church’s wool­ly mam­moth re­vival biotech Colos­sal spins out com­pu­ta­tion­al bio out­fit

Lei Lei Wu

News Reporter

Colos­sal Bio­sciences has a some­what lofty goal — re­vive the wool­ly mam­moth. When the biotech launched in 2021, its CEO Ben Lamm com­pared its mis­sion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times